|
US2017081623A1
|
|
Gas delivery devices and associated systems and methods
|
|
US2015218247A1
|
|
Taci as an anti-tumor agent
|
|
CN106459002A
|
|
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
WO2015089327A1
|
|
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
WO2015085276A1
|
|
Population pharmacokinetics tools and uses thereof
|
|
WO2015070014A1
|
|
Procoagulant fusion compound
|
|
WO2015057939A1
|
|
Anti-s1p4 antibodies and uses thereof
|
|
WO2015057824A1
|
|
Transgenic animals for in vivo imaging
|
|
WO2015042580A1
|
|
Compositions and methods for treatment of neuropathic pain
|
|
US2015064177A1
|
|
Therapeutic uses of humanized antibodies against alpha-4 integrin
|
|
WO2015023894A1
|
|
Recombinant factor viii proteins
|
|
TN2014000321A1
|
|
Pharmaceutical compositions containing dimethyl fumarate
|
|
AU2014203116A1
|
|
Methods for Pancreatic Tissue Regeneration
|
|
TW201536811A
|
|
Chimeric FVII-XTEN molecules and uses thereof
|
|
WO2014190056A2
|
|
Prodrugs and drugs
|
|
WO2014179665A1
|
|
Methods for increasing polypeptide recovery
|
|
WO2014145208A1
|
|
Hydrophobic interaction protein chromatography under no-salt conditions
|
|
WO2014144616A2
|
|
Anti-alpha v beta 5 antibodies and uses thereof
|
|
WO2014130811A1
|
|
Interferon beta formulation
|
|
WO2014120862A1
|
|
Assay for detection of jc virus dna
|
